The combination of atezolizumab-bevacizumab has been proven to be superior to sorafenib for the treatment of unresectable hepatocellular carcinoma not amenable to locoregional treatments, becoming the standard of care of systemic therapy.
Stefanini, B., Bucci, L., Santi, V., Reggidori, N., Rampoldi, D., Lani, L., et al. (2022). Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors. DIGESTIVE AND LIVER DISEASE, 54(11), 1563-1572 [10.1016/j.dld.2022.07.003].
Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors
Stefanini, Benedetta;Bucci, Laura;Reggidori, Nicola;Rampoldi, Davide;Lani, Lorenzo;Granito, Alessandro;Trevisani, Franco
2022
Abstract
The combination of atezolizumab-bevacizumab has been proven to be superior to sorafenib for the treatment of unresectable hepatocellular carcinoma not amenable to locoregional treatments, becoming the standard of care of systemic therapy.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
